BIOSURGERY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Biosurgery Market Size and Share Analysis: (2026 - 2033)

The global biosurgery market is estimated to be valued at USD 19,115.8 Mn in 2026 and is projected to grow at a compound annual growth rate (CAGR) of 6.6% during the forecast period (2026-2033), reaching USD 29,899.4 Mn by 2033. This growth can be attributed rising number of surgical procedures, increasing prevalence of chronic diseases and trauma cases, and growing demand for minimally invasive surgeries.

Key Takeaways from the Biosurgery Market Report

• Haemostatic agents segment is expected to lead the market with a share of 34% in 2026 due to their widespread use in controlling surgical bleeding, rising number of complex surgical procedures, and increasing preference for advanced blood-loss management products in hospitals. For example, Johnson & Johnson MedTech received U.S. FDA approval for its ETHIZIA hemostatic sealing patch designed for challenging surgical bleeding control, reflecting continued innovation and growing clinical demand for advanced hemostatic solutions.
• General surgery segment is slated to account for the largest market share of over 32% in 2026 on account of high global surgical procedure volumes and increasing adoption of biosurgery products for effective wound closure, bleeding control, and post-operative complication management.
• North America is projected to retain its dominance over the global biosurgery industry, capturing a share of 40% in 2026, owing to high surgical volumes, advanced healthcare infrastructure, and growing adoption of minimally invasive surgeries. For instance, according to the American Hospital Association, U.S. hospitals perform millions of inpatient surgical procedures annually, supported by increasing investments in advanced surgical technologies.
• Asia Pacific, holding a share of 24% in 2026, is poised to emerge as the fastest growing market for biosurgery during the forecast period, thanks to rising healthcare expenditure, increasing number of surgeries performed, expanding hospital infrastructure, and growing awareness regarding advanced surgical care solutions. For example, according to the India Brand Equity Foundation, India’s healthcare market was estimated to reach US$ 638 billion by 2025, supporting greater adoption of advanced surgical and biosurgery technologies across the region.

Biosurgery Market Overview

The global biosurgery market is poised to exhibit steady growth during the forecast period. This is due to rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, growing adoption of advanced hemostatic and sealant products. Similarly, rising volume of surgical procedures worldwide and continuous technological advancements in biosurgical products are supporting market expansion.

Rising number of road accidents, sports injuries, trauma cases, and elective surgeries is fueling demand for effective blood-loss management and wound closure products. Biosurgery products are increasingly preferred over traditional sutures and staples because they improve surgical efficiency and reduce complications.

Growing adoption of surgical sealants and adhesives is a key growth-shaping trend in the biosurgery market. Surgical sealants and adhesives are among the fastest-growing segments because they provide superior tissue adhesion, lower infection risks, and reduced operating time compared to conventional closure methods.

Biosurgery Market Growth Drivers

Increasing Prevalence of Chronic Diseases: Rising prevalence of chronic conditions such as cardiovascular diseases, cancer, diabetes, orthopedic disorders, and obesity is increasing the number of surgical interventions worldwide. For instance, according to the This, in turn, is providing a strong impetus for the growth of the biosurgery market. Patients with chronic conditions often require enhanced wound management and tissue regeneration solutions, thereby boosting the demand for biosurgery products.

Biosurgery Market Opportunities

Rising Demand for Minimally Invasive Surgeries (MIS): Minimally invasive and robotic-assisted procedures are growing across orthopedic, cardiovascular, neurological, and general surgeries. These procedures require advanced biosurgical products for effective bleeding control, tissue sealing, and faster healing. Biosurgery solutions help reduce hospital stays, minimize complications, and improve patient recovery outcomes. Thus, increasing popularity of minimally invasive surgeries is expected to create lucrative growth opportunities for the biosurgery market during the forecast period.

Biosurgery Market Trends

Advancements in Biomaterials and Tissue Engineering: Continuous innovations in biomaterials, regenerative medicine, and tissue engineering are paving the way for the development of next-generation biosurgery products with improved biocompatibility, faster healing capabilities, and enhanced surgical precision. Manufacturers are increasingly developing synthetic and hybrid sealants, sprayable fibrin glues, hydrogels, and bioactive scaffolds for a wider range of surgical applications. These advancements are expected to support the growth of the biosurgery market in the coming years.

Current Events and Their Impact on the Biosurgery Market

Segmental Insights

Which Treatment Type Dominates the Biosurgery Market?

Haemostatic Agents Lead the Market with Over One-Third Share in 2026

According to Coherent Market Insights’ latest biosurgery market analysis, haemostatic agents segment is set to lead the market with a share of 34% in 2026. This dominance can be attributed to rising number of surgical procedures worldwide, growing prevalence of trauma and chronic diseases, and increasing demand for effective blood loss management during surgeries.

Haemostatic agents are widely used in cardiovascular, orthopedic, neurological, and general surgical procedures due to their ability to rapidly control bleeding and improve patient outcomes. In addition, technological advancements in advanced haemostatic products, including thrombin-based agents, gelatin sponges, oxidized regenerated cellulose, and combination haemostats, are also boosting segment growth.

Which Disease Type Dominates the Biosurgery Industry?

General Surgery to Account for Nearly 1/3^rd of the Global Market Revenue in 2026

By disease type, general surgery segment is expected to dominate the global biosurgery market, accounting for a revenue share of more than 32% in 2026. This is attributable to the rising volume of surgical procedures worldwide, increasing adoption of hemostatic agents and sealants in complex surgeries, and growing preference for minimally invasive surgical techniques.

Biosurgery products are widely utilized in general surgeries to control bleeding, prevent tissue leakage, and accelerate wound healing, thereby improving patient outcomes and reducing post-operative complications. In addition, increasing prevalence of chronic diseases, expanding geriatric population, and advancements in surgical technologies are expected to boost growth of the target segment during the forthcoming period.

Regional Insights

High Chronic Disease Burden Driving Demand in North America

North America is expected to dominate the global biosurgery market with a 40% share in 2026. This can be attributed to advanced healthcare infrastructure, high surgical procedure volumes, and growing adoption of minimally invasive surgeries. Increasing prevalence of chronic diseases such as cardiovascular disorders, cancer, and obesity is also fueling demand for biosurgery products like surgical sealants, hemostats, and adhesion barriers.

According to the U.S. CDC, approximately 51.4 million inpatient procedures, including many surgical procedures, are performed annually in the United States. The large volume of surgeries significantly boosts demand for biosurgery products used for bleeding control, tissue sealing, and wound healing during surgical procedures.

Rising Geriatric Population Boosting Biosurgery Product Sales in Asia Pacific

Asia Pacific is forecast to emerge as a hotbed for manufacturers of biosurgery products during the forecast period, capturing a global market share of 24% in 2026. This is mainly due to a rapidly aging population, rising healthcare expenditure, and increasing adoption of minimally invasive and robotic-assisted surgeries.

The aging population is more prone to degenerative diseases and surgeries such as joint replacements, cardiovascular procedures, and reconstructive surgeries. Older patients also require faster healing and reduced post-operative complications, which supports adoption of biosurgical materials and biologic sealants. Thus, expanding geriatric population is expected to boost growth of the Asia Pacific biosurgery market during the forecast period.

Biosurgery Market Outlook – Country-wise

U.S. Biosurgery Market Trends

The United States is expected to remain a leading market for biosurgery products during the forecast period. This is mostly due to increasing prevalence of chronic diseases and growing adoption of minimally invasive procedures. According to the American College of Surgeons, millions of surgical procedures are performed annually in the United States, creating strong demand for biosurgery products such as hemostats, surgical sealants, and adhesion barriers for effective bleeding management and wound healing.

China Biosurgery Market Forecast

China’s biosurgery market is poised to witness robust growth during the assessment period owing to rapid expansion of healthcare infrastructure, rising surgical procedures, and increasing aging population. According to China’s National Bureau of Statistics (2025 release), the country’s population aged 60 years and above reached 323.4 million, accounting for 23.0% of the total population. This demographic trend is significantly increasing the prevalence of age-related disorders and surgical interventions, thereby driving demand for biosurgery products used in orthopedic, cardiovascular, and general surgeries.

Who are the Major Companies in the Biosurgery Market?

Some of the major players in Biosurgery Market are Betatech Medical, Hemostasis LLC, CryoLife Inc., CSL Limited, Medtronic PLC, Johnson & Johnson, B.Braun Melsungen AG, Baxter International Inc., Integra Lifesciences Holdings Corporation, and Becton, Dickinson and Company (CR Bard), among others.

Key Strategies Adopted by Industry Players

Leading companies in the biosurgery market are adopting various strategies to boost their revenue as well as gain a competitive edge over the industry. These include AI-enabled surgical innovations, strategic partnerships, acquisitions, robotic surgery expansion, and new product launches.

For example, in 2025, Companies are also focusing on minimally invasive and robotic-assisted surgery technologies through collaborations and acquisitions.

• In January 2026, Johnson & Johnson submitted its OTTAVA robotic surgical system to the U.S. Food and Drug Administration for review. The submission is part of the process to seek regulatory approval before the system can be used in hospitals.
• In October 2025, Integra LifeSciences announced its participation in the CNS Annual Meeting. The company planned to showcase its neurosurgery and regenerative medicine products at the event.
• In August 2025, AROA announced the findings of its first-in-human clinical study of the ENIVO platform technology. The platform is designed to manage surgical “dead space,” which is a potential cavity created after tissue dissection or excision that may fill with fluid such as seroma.
• In April 2025, Baxter launched a room-temperature version of its HEMOPATCH Sealing Hemostat. The updated product can be stored without refrigeration, making it easier to use during surgery.

Market Report Scope

Analyst Opinion (Expert Opinion)

• The biosurgery market is growing due to the rising number of surgeries worldwide, especially orthopedic, cardiovascular, and general surgeries. Biosurgery products such as sealants and hemostatic agents help reduce blood loss and improve healing during operations.
• According to the International Society of Aesthetic Plastic Surgery (ISAPS), more than 15.8 million surgical cosmetic procedures were performed globally in 2023, representing a 5.5% increase from the previous year. The continued rise in aesthetic surgeries highlights growing demand for advanced surgical and wound management products used in biosurgery.
• Increasing adoption of minimally invasive and robotic-assisted surgeries is boosting demand for biosurgery products because these procedures require advanced tissue sealing and bleeding control solutions.

Market Segmentation

• By Treatment Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • Hemostatic Agents
  • Bone-graft Substitutes
  • Surgical Sealants and Adhesives
  • Soft-tissue Attachments
  • Adhesion Barriers
  • Staple Line Reinforcement
• By Disease Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • Orthopedic Surgery
  • General Surgery
  • Neurological Surgery
  • Cardiovascular Surgery
  • Gynecological Surgery
  • Other Applications
• By Region Insights ( Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
• Key Players in the Biosurgery Market
  • Betatech Medical
  • Hemostasis LLC
  • CryoLife Inc.
  • CSL Limited
  • Medtronic PLC
  • Johnson & Johnson
  • Braun Melsungen AG
  • Baxter International Inc.
  • Integra Lifesciences Holdings Corporation
  • Becton, Dickinson and Company (CR Bard)

Sources

Primary Research interviews

• Interviews with biosurgery product manufacturers, distributors, hospital procurement managers, surgeons, healthcare professionals, regulatory experts, and industry specialists across major regions.

Databases

• PubMed
• ScienceDirect
• ClinicalTrials.gov
• FDA Database
• EMA Database
• WHO Database
• OECD Health Statistics
• World Bank Database
• UN Comtrade Database
• Eurostat
• National Center for Biotechnology Information (NCBI)

Magazines

• Medical Device and Diagnostic Industry (MD+DI)
• MedTech Outlook
• Healthcare Business Today
• Biomedical Instrumentation & Technology
• Hospital Management Magazine

Journals

• Journal of Surgical Research
• International Journal of Surgery
• Journal of Biomedical Materials Research
• Annals of Surgery
• Surgical Innovation
• Journal of Wound Care

Newspapers

• The Wall Street Journal
• Financial Times
• The New York Times
• USA Today
• The Economic Times
• Business Standard

Associations

• American College of Surgeons
• Association of periOperative Registered Nurses
• Advanced Medical Technology Association
• European Society of Surgery
• International Society for Burn Injuries

Public Domain sources

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Organization for Economic Co-operation and Development (OECD)
• Government health ministry publications
• Healthcare statistics portals, annual reports, investor presentations, and company white papers

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years.